Identification BCL6 and miR-30 family associating with Ibrutinib resistance in activated B-cell-like diffuse large B-cell lymphoma

Ibrutinib has clear efficacy for activated B-cell-like diffuse large B cell lymphoma (ABC-DLBCL) in previous clinical researches. However, the resistance of Ibrutinib has limited its therapeutic benefit and the potential mechanism remains unclear. This study was aimed to identify potential candidate...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jiazheng, Huang, Yan, Zhang, Yun, Wen, Jingjing, Chen, Yanxin, Wang, Lingyan, Jiang, Peifang, Hu, Jianda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7904539/
https://www.ncbi.nlm.nih.gov/pubmed/33629212
http://dx.doi.org/10.1007/s12032-021-01470-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7904539/
https://www.ncbi.nlm.nih.gov/pubmed/33629212
http://dx.doi.org/10.1007/s12032-021-01470-5

Ejemplares similares